{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:03:29Z","timestamp":1750133009587,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Project of Science and Technology Research of the Department of Education of Jiangxi Province","award":["GJJ211527"],"award-info":[{"award-number":["GJJ211527"]}]},{"name":"the Guiding Scientific and Technological Plan Project of Ganzhou","award":["GZ2024ZSF844"],"award-info":[{"award-number":["GZ2024ZSF844"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Primary drug resistance (PDR) is an important cause of antiretroviral therapy (ART) failure. However, the prevalence and characteristics of PDR in Ganzhou remain unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From July 2018 to August 2021, treatment-na\u00efve, newly diagnosed HIV-infected individuals in Ganzhou, China were recruited. Blood samples were collected, and the HIV <jats:italic>pol<\/jats:italic> gene was amplified by nested PCR followed by Sanger sequencing. Sequence editing and assembly were performed using DNASTAR Lasergene software, and subsequent analysis for resistance mutations and drug susceptibility profiling was conducted using the Stanford University HIV Drug Resistance Database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 108 successfully amplified samples, seven exhibited low-, intermediate-, or high-level resistance mutations, resulting in a PDR prevalence of 6.5%. Among them, the mutation rate of non-nucleoside reverse transcriptase inhibitors (NNRTIs) was 4.6%, and the drug resistance mutation rates of nucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors (INSTIs) were both 0.9%. No protease inhibitor resistance was detected. Nine drug resistance mutations were detected, among which six were related to NNRTIs, one was related to nucleoside reverse transcriptase inhibitors, and two were related to INSTIs. The K103N and Y181C mutations conferred intermediate-to-high resistance to NNRTIs, while A98G and V179E caused low-to-intermediate resistance to NNRTIs, and the remaining mutations led to low drug resistance to the respective drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared to other regions in China, Ganzhou exhibits a relatively low PDR among newly diagnosed HIV-infected individuals. However, the emergence of INSTI-resistant strains underscores the need for enhanced resistance surveillance to prevent the spread of drug-resistant strains caused by ART failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12981-025-00758-0","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T13:29:53Z","timestamp":1750080593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief communication: characteristics of primary drug resistance in newly diagnosed HIV-infected individuals in Ganzhou, China"],"prefix":"10.1186","volume":"22","author":[{"given":"Dan-Dan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Zhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"758_CR1","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2352-3018(23)00272-2","volume":"11","author":"A Trickey","year":"2024","unstructured":"Trickey A, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies. Lancet HIV. 2024;11:e176\u201385.","journal-title":"Lancet HIV"},{"key":"758_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jac\/dky382","volume":"74","author":"A Keita","year":"2019","unstructured":"Keita A, et al. Impact of HIV-1 primary drug resistance on the efficacy of a first-line antiretroviral regimen in the blood of newly diagnosed individuals in bamako, Mali. J Antimicrob Chemother. 2019;74:165\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"758_CR3","unstructured":"World Health Organization. HIV drug resistance: brief report 2024. 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376039\/9789240086319-eng.pdf?sequence=1. Accessed 10 May 2025."},{"key":"758_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12889-021-10580-8","volume":"21","author":"C Wu","year":"2021","unstructured":"Wu C, et al. Impact of immediate initiation of antiretroviral therapy among men who have sex with men infected with HIV in chengdu, Southwest china: trends analysis, 2008\u20132018. BMC Public Health. 2021;21:689.","journal-title":"BMC Public Health"},{"key":"758_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/jac\/dkad175","volume":"78","author":"D Zhang","year":"2023","unstructured":"Zhang D, et al. Increased prevalence and stable clustering rate of HIV-1 transmitted drug resistance strains after \u2018treat-all\u2019 in a megacity of China. J Antimicrob Chemother. 2023;78:1795\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"758_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.46234\/ccdcw2023.129","volume":"5","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Changes in HIV-1 Subtypes\/Sub-Subtypes, and transmitted drug resistance among ART-Na\u00efve HIV-Infected Individuals - China, 2004\u20132022. China CDC Wkly. 2023;5:664\u201371.","journal-title":"China CDC Wkly"},{"key":"758_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/aid.2020.0168","volume":"37","author":"YN Xie","year":"2021","unstructured":"Xie YN, et al. The genetic diversity of HIV-1 within Antiretroviral-Naive outpatients in ganzhou, China. AIDS Res Hum Retroviruses. 2021;37:147\u201350.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"758_CR8","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/jac\/dkab296","volume":"76","author":"YN Xie","year":"2021","unstructured":"Xie YN, et al. Distribution characteristics of drug resistance mutations of HIV CRF01_AE, CRF07_BC and CRF08_BC from patients under ART in ganzhou, China. J Antimicrob Chemother. 2021;76:2975\u201382.","journal-title":"J Antimicrob Chemother"},{"key":"758_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18:346\u201355.","journal-title":"Lancet Infect Dis"},{"key":"758_CR10","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/infdis\/jiae303","volume":"230","author":"J Ye","year":"2024","unstructured":"Ye J, et al. Trends and patterns of HIV transmitted drug resistance in China from 2018 to 2023. J Infect Dis. 2024;230:1410\u201321.","journal-title":"J Infect Dis"},{"key":"758_CR11","first-page":"1129","volume":"43","author":"R-R Yang","year":"2023","unstructured":"Yang R-R, et al. Analysis of AIDS epidemic changes and characteristics in Ganzhou City from 2011 to 2021. J Gannan Med Univ. 2023;43:1129\u201333. (in Chinese).","journal-title":"J Gannan Med Univ"},{"key":"758_CR12","first-page":"1458","volume":"25","author":"N Zhang","year":"2015","unstructured":"Zhang N, et al. Analysis of subtype and transmitted drug resistance among part HIV infections under 25 year-old in Jiangxi Province in 2013. Chin J Health Lab Technol. 2015;25:1458\u201360. (in Chinese).","journal-title":"Chin J Health Lab Technol"},{"key":"758_CR13","first-page":"1289","volume":"21","author":"N Zhang","year":"2017","unstructured":"Zhang N, et al. HIV-1 molecular epidemiological investigation and drug resistance in Jiangxi Province in 2015. Chin J Dis Control Prev. 2017;21:1289\u201391. (in Chinese).","journal-title":"Chin J Dis Control Prev"},{"key":"758_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf159","author":"J Hao","year":"2025","unstructured":"Hao J, et al. Transmitted human immunodeficiency virus type 1 (HIV-1) drug resistance among newly diagnosed individuals in 31 Provincial-Level administrative divisions in China in 2023: A Cross-sectional survey. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf159. (online ahead of print).","journal-title":"Clin Infect Dis"},{"key":"758_CR15","doi-asserted-by":"publisher","first-page":"1475548","DOI":"10.3389\/fmicb.2024.1475548","volume":"15","author":"M Zhu","year":"2024","unstructured":"Zhu M, et al. Epidemiological dynamics and molecular characterization of HIV drug resistance in Eastern China from 2020 to 2023. Front Microbiol. 2024;15:1475548.","journal-title":"Front Microbiol"},{"key":"758_CR16","first-page":"441","volume":"30","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Joinpoint regression analysis of the trend of transmitted drug resistance prevalence among ART-na\u00efve HIV infected patients in China from 2004 to 2022. Int J Virol. 2023;30:441\u20136. (in Chinese).","journal-title":"Int J Virol"},{"key":"758_CR17","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00705-021-05140-9","volume":"166","author":"H Yuan","year":"2021","unstructured":"Yuan H, et al. Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in china, 2000\u20132016. Arch Virol. 2021;166:2451\u201360.","journal-title":"Arch Virol"},{"key":"758_CR18","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1128\/AAC.46.11.3437-3446.2002","volume":"46","author":"KL White","year":"2002","unstructured":"White KL, et al. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R\u2009+\u2009M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother. 2002;46:3437\u201346.","journal-title":"Antimicrob Agents Chemother"},{"key":"758_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/QAD.0b013e3280187505","volume":"21","author":"FA Frankel","year":"2007","unstructured":"Frankel FA, et al. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS. 2007;21:665\u201375.","journal-title":"AIDS"},{"key":"758_CR20","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/QAI.0000000000003039","volume":"91","author":"CL Li","year":"2022","unstructured":"Li CL, et al. The effect of pretreatment potential resistance to NNRTIs on antiviral therapy in patients with HIV\/AIDS. J Acquir Immune Defic Syndr. 2022;91:S27\u201334.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00758-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T13:29:54Z","timestamp":1750080594000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00758-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["758"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00758-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol has been approved by the Ethics Committee of Gannan Medical University (approval number: 2018037; approval date: February 26, 2018). Written informed consent was obtained from all participants before the collection of whole blood samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}